Oculis: Advancing Privosegtor in Optic Neuritis and MS Relapses Supports Buy Rating and Unchanged $26 Price TargetTip Ranks·1 day ago, 09:55 AMOCS-1.67%
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis | OCS Stock NewsStockTitan·2 days ago, 07:00 PMOCS-1.67%
Oculis To Acquire Rights To Privosegtor, ACT-02 From Accure Therapeutics; Shares Uprttnews·Aug 10 at 03:55 AMOCS-1.67%
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company | OCS Stock NewsStockTitan·Aug 9 at 06:01 PMOCS-1.67%
Oculis Q2 2026 loss narrows on CHF 12.1 million warrant valuation gain, FX swing to profitPUBT·Aug 6 at 04:26 PMOCS-1.67%
Oculis Q2 2026 Results: Cash Runway Reaches the Second Half of 2029TradingKey·Aug 6 at 04:04 PMOCS-1.67%
